COST-CONSEQUENCE ANALYSIS COMPARING ROMIPLOSTIM TO RITUXIMAB IN THE TREATMENT OF ADULT PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN GERMANY

被引：0
|
作者：
von Depka, M. [1 ]
Salama, A. [2 ]
Perrin, A. [3 ]
Oelze, I. [3 ]
Chulikavit, M. [3 ]
Kunz, E. [4 ]
Kutikova, L. [4 ]
Thalheimer, M. [5 ]
机构：
[1] Werlhof Inst, Hannover, Germany
[2] Charite Univ Med Berlin, Inst Transfus Med, Berlin, Germany
[3] Analyt LA SER Int Inc, New York, NY USA
[4] Amgen GmbH, Munich, Germany
[5] Univ Klinikum Heidelberg, Heidelberg, Germany
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1045
引用
收藏
页码：427 / 427
页数：1
相关论文
共 50 条
  • [21] A PHARMACOECONOMIC EVALUATION OF ROMIPLOSTIM (NPLATE®) FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN MEXICO
    Arocho, R.
    Northridge, K.
    Rivera Hurtado, R.
    Garcia Chavez, J.
    VALUE IN HEALTH, 2011, 14 (03) : A62 - A62
  • [22] Romiplostim as early treatment for refractory primary immune thrombocytopenia
    Anne Contis
    Estibaliz Lazaro
    Carine Greib
    Jean-Luc Pellegrin
    Jean-François Viallard
    International Journal of Hematology, 2013, 98 : 520 - 524
  • [23] Romiplostim as early treatment for refractory primary immune thrombocytopenia
    Contis, Anne
    Lazaro, Estibaliz
    Greib, Carine
    Pellegrin, Jean-Luc
    Viallard, Jean-Francois
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (05) : 520 - 524
  • [24] TREATMENT OF ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WITH ROMIPLOSTIM IN ROUTINE CLINICAL PRACTICE IN GERMANY-INTERIM RESULTS FROM AN OBSERVATIONAL STUDY (PLATEAU)
    Welslau, M.
    Reiser, M.
    Illmer, T.
    Josten, K.
    Dietzfelbinger, H.
    Seitz, A.
    HAEMATOLOGICA, 2014, 99 : 204 - 204
  • [25] Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis
    Wang, Jia
    Li, Ya
    Wang, Chong
    Zhang, Yayue
    Gao, Chong
    Lang, Haiyan
    Chen, Xinyi
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [26] Immunomodulation with Romiplostim in Young Adult Primary Immune Thrombocytopenia (ITP) As Second-Line Strategy (iROM-study)
    Schifferli, Alexandra
    Ruefer, Axel
    Rovo, Alicia
    Cantoni, Nathan
    Holbro, Andreas
    Favre, Genevieve
    Faeth, Heike
    Pereira, Renata Rosa
    Wieland, Anna
    Dirks, Jan
    Nimmerjahn, Falk
    Kuehne, Thomas
    BLOOD, 2021, 138
  • [27] Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia
    Patwardhan, Pallavi
    Proudman, David
    Allen, Jeffrey
    Lucas, Sedge
    Nellesen, Dave
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (10): : 1447 - 1456
  • [28] Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland
    Lee D.
    Thornton P.
    Hirst A.
    Kutikova L.
    Deuson R.
    Brereton N.
    Applied Health Economics and Health Policy, 2013, 11 (5) : 457 - 469
  • [29] Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain
    Ramon Gonzalez-Porras, Jose
    Parrondo Garcia, Francisco Javier
    Anguita, Eduardo
    FARMACIA HOSPITALARIA, 2020, 44 (06) : 279 - 287
  • [30] COST OF ELTROMBOPAG AND RITUXIMAB BY PATIENT RESPONDENT TO THE TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA IN SPAIN
    Anguita, E.
    Parrondo-Garcia, F. J.
    Roldan-Etcheverry, J. J.
    Gonzalez-Porras, J. R.
    HAEMATOLOGICA, 2019, 104 : 107 - 107
12345